Document is current
Any future updates will be listed below
-
Authors
Huwart, Sabrina J. P.
Fayt, Clémence
Gangarossa, Giuseppe
Luquet, Serge
Cani, Patrice D.
Everard, Amandine
-
Funding
Funding for this research was provided by:
Fonds De La Recherche Scientifique - FNRS (J.0075.22 and T.0115.24)
FNRS FRFS-WELBIO (WELBIO-CR-2019S-03R and WELBIO-CR-2019S-03E)
- License Information
-
More Information
Article History
Received: 20 August 2024
Accepted: 13 November 2024
First Online: 23 November 2024
Declarations
:
: The mouse experiments were approved by the UCLouvain Health Sector’s ethical committee (approval numbers: 2022/UCL/MD/05, 2023/UCL/MD/A5, and 2023/UCL/MD/A12), conducted in accordance with the local ethics committee guidelines and compliant with the Belgian Law of May 29, 2013, concerning the protection of laboratory animals (agreement numbers: LA1230314 and LA2230641).
: A.E. and P.D.C. are inventors on patent applications dealing with the use of A. muciniphila and its components in the treatment of metabolic disorders. A. E., SJPH and P.D.C. are inventors on patent applications dealing with gut microbes in food reward dysregulations. P.D.C. was cofounder of The Akkermansia company SA and Enterosys. All other authors declare they have no competing interests. The funders had no role: in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
